Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (121-130 of 342) with videos related to

Pageof 35
Sort By:
Rheumatology (Oxford, England)|June 21, 2023
The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance studyPhilip S Helliwell, Laura C Coates, Myka Ransom, et al.
The Journal of Rheumatology|February 16, 2021
Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare QuestionnairePhilip S Helliwell, William Tillett, Robin Waxman, et al.
RMD Open|August 31, 2023
Developing evidence-based patient-focused learning materials to support health behaviour change for people living with psoriatic arthritisLouise Hailey, Laura Howells, Christine Bundy, et al.
BMC Musculoskeletal Disorders|July 20, 2017
The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomesGabriele De Marco, Philip Helliwell, Dennis McGonagle, et al.
RMD Open|January 5, 2018
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1Laura C Coates, Mitsumasa Kishimoto, Alice Gottlieb, et al.
Rheumatology (Oxford, England)|October 18, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialArthur Kavanaugh, Laura C Coates, Philip J Mease, et al.
BMJ Open|April 23, 2024
Qualitative interview study of rheumatology patients' experiences of COVID-19 shielding to explore the physical and psychological impact and identify associated support needsChristine A Silverthorne, Bethan Jones, Mel Brooke, et al.
Clinical Rheumatology|July 12, 2022
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Rheumatology Advances in Practice|April 24, 2023
The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort studyMagnus B Petersen, Rebekka L Hansen, Alexander Egeberg, et al.
Therapeutic Advances in Musculoskeletal Disease|January 17, 2022
Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility studyInes Rombach, Laura Tucker, William Tillett, et al.
Pageof 35

Showing results (121-130 of 342) with videos related to

Sort By:
Pageof 35
Rheumatology (Oxford, England)|June 21, 2023
The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance studyPhilip S Helliwell, Laura C Coates, Myka Ransom, et al.
The Journal of Rheumatology|February 16, 2021
Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare QuestionnairePhilip S Helliwell, William Tillett, Robin Waxman, et al.
RMD Open|August 31, 2023
Developing evidence-based patient-focused learning materials to support health behaviour change for people living with psoriatic arthritisLouise Hailey, Laura Howells, Christine Bundy, et al.
BMC Musculoskeletal Disorders|July 20, 2017
The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomesGabriele De Marco, Philip Helliwell, Dennis McGonagle, et al.
RMD Open|January 5, 2018
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1Laura C Coates, Mitsumasa Kishimoto, Alice Gottlieb, et al.
Rheumatology (Oxford, England)|October 18, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialArthur Kavanaugh, Laura C Coates, Philip J Mease, et al.
BMJ Open|April 23, 2024
Qualitative interview study of rheumatology patients' experiences of COVID-19 shielding to explore the physical and psychological impact and identify associated support needsChristine A Silverthorne, Bethan Jones, Mel Brooke, et al.
Clinical Rheumatology|July 12, 2022
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Rheumatology Advances in Practice|April 24, 2023
The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort studyMagnus B Petersen, Rebekka L Hansen, Alexander Egeberg, et al.
Therapeutic Advances in Musculoskeletal Disease|January 17, 2022
Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility studyInes Rombach, Laura Tucker, William Tillett, et al.
Pageof 35